BGI Genomics Company Description

BGI Genomics Co., Ltd. provides sequencing services and a portfolio of genetic tests for medical institutions, research institutions, and other public and private partners in China and internationally.

The company offers DNA, RNA, and customized sequencing services; and non-invasive prenatal testing, reproductive health screening, newborn genetic screening, and clinical exome sequencing services, as well as clinical and research solutions for oncology.

It also offers laboratory solutions for the detection and diagnosis of patients suspected with COVID-19; SARS-CoV-2 IgM and IgG antibody detection kit; and real-time fluorescent RT-PCR kit for detecting SARS-CoV-2.

The company offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery.

The company was formerly known as Shenzhen BGI Medicine Co., Ltd. and changed its name to BGI Genomics Co., Ltd. in 2015.

BGI Genomics Co., Ltd. was founded in 1999 and is headquartered in Shenzhen, China.

BGI Genomics Co., Ltd.

Country	China
Founded	1999
Industry	Diagnostics & Research
Sector	Healthcare
Employees	3,752
CEO	Lijian Zhao

Contact Details

Address: Building No.7 Shenzhen, 518083 China
Phone	86 755 2527 3120
Website	bgi.com

Stock Details

Ticker Symbol	300676
Exchange	Shenzhen Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
ISIN Number	CNE100003449
SIC Code	2836

Key Executives

Name	Position
Lijian Zhao	Non Independent Director and GM
Yujue Wang	Chief Financial Officer, Deputy GM and Non Independent Director
Qian Xu	Director of Legal Affairs, General Counsel, Deputy GM and Secretary
Ning Li	Non Independent Director and Deputy GM
Zhu Shida	Non Independent Director and Deputy General Manager
Weijun Chen	Deputy General Manager
Hui Liu	Head of the accounting department and Accounting Supervisor